Furthermore, targeting PRMT5 in immunocompromised mice with lung cancer resulted in reduced tumor progression; however, the treatment effect was reduced significantly in immunocompetent mice and associated with increased PD-L1 expression in the tumor tissue. Here, PRMT5 is linked to lung cancer.